Amit Technion

Rona Samler leads AMIT as CEO and concurrently serves as Chief Business Officer of the Technion R&D Foundation, giving her oversight of both the capital allocation and the origination pipeline. The dual role concentrates investment decision-making at the intersection of research commercialization and venture funding.

AMIT's deal flow originates almost entirely from Technion's own research laboratories and faculty spinouts. The firm functions as the university's dedicated investment arm for life sciences, reviewing intellectual property that emerges from campus R&D before it reaches external venture markets. This campus-gated model limits volume but ensures proprietary access to foundational Israeli science.

AMIT is neither—it is an asset manager structured as the investment arm of the Technion – Israel Institute of Technology. It is not a traditional limited-partner venture firm raising blind pools; rather, it operates as a tech-transfer funding mechanism supported by philanthropic founding partners like the Alfred E. Mann Foundation.

AMIT targets early-stage investments, specifically Seed and Start-up rounds for companies spinning out of Technion research. The firm participates at the formation and proof-of-concept stages, often as the first institutional capital into a company before broader syndication.

The investment mandate concentrates on life sciences, including medical devices, digital health, and AI/ML applications emerging from the Technion's engineering and biomedical faculties. The firm does not operate as a generalist investor and restricts its pipeline to domains with direct university research lineage.